Form 4: PLUS THERAPEUTICS CFO Vests Over 67,000 Shares

PLUS THERAPEUTICS, INC. Chief Financial Officer, Andrew Sims, reported the vesting of 67,452 Restricted Stock Units into common stock.

Summary

• Andrew John Hugh MacIntyre Sims, Chief Financial Officer of PLUS THERAPEUTICS, INC. (PSTV), reported transactions on April 1, 2026.
• Sims acquired 38,323 shares of common stock through the vesting of Restricted Stock Units (RSUs) at a price of $0.
• Sims also acquired an additional 29,129 shares of common stock through the vesting of RSUs at a price of $0.
• Following these transactions, Sims directly beneficially owns 173,913 shares of common stock.
• The vesting of 38,323 RSUs is part of a grant that vests in twelve substantially equal quarterly installments, beginning October 1, 2025.
• The vesting of 29,129 RSUs is part of a grant that vests in twelve substantially equal quarterly installments, beginning April 1, 2026.
• After these vestings, Sims holds 694,451 unvested Restricted Stock Units from the first grant and 665,322 unvested Restricted Stock Units from the second grant.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation and a minor increase in insider ownership, which generally signals confidence.

Positives

• The vesting of RSUs indicates continued long-term incentive alignment between the Chief Financial Officer and shareholder interests.
• The increase in direct common stock ownership by a key executive can be viewed as a positive signal of confidence in the company's future.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's financial performance or strategic direction, beyond the scheduled vesting of executive compensation.

Industry Context

StockSavvy.ai notes that RSU vesting is a standard component of executive compensation packages in the biotechnology and pharmaceutical industries, designed to align management incentives with long-term shareholder value. This transaction reflects a routine compensation event rather than a strategic business development.

Related Party Transactions

• The vesting of Restricted Stock Units for the Chief Financial Officer is a routine compensation-related transaction between an executive and the company.

Stakeholder Impact

• Shareholders: The increase in direct ownership by the CFO may be perceived as a positive signal of management's alignment with shareholder interests.
• Employees: This transaction is part of a standard executive compensation structure, which can influence employee morale and retention strategies.

Next Steps

• Continued vesting of the remaining 694,451 and 665,322 Restricted Stock Units in future quarterly installments as per the original grant schedules.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled vesting of Restricted Stock Units for a key executive. While it slightly increases insider ownership, it does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It is an expected compensation event.

Keywords

PLUS THERAPEUTICS, PSTV, Andrew Sims, CFO, Form 4, SEC filing, Restricted Stock Units, RSU vesting, insider transaction, common stock